Background {#Sec1}
==========

Nasopharyngeal carcinoma (NPC) is a unique malignancy, which has distinguishing features from other head and neck cancer in terms of epidemiology, geographic areas, population, and prognosis. In 2012, approximately 86,700 new cases of NPC were reported, accounting for 0.6% of all cancers and causing 50,800 deaths \[[@CR1], [@CR2]\]. The area with the highest incidence is southern China, especially provinces such as Guangdong, Hainan, Guangxi, Hunan, and Fujian \[[@CR3]\]. NPC is sensitive to both radiation and chemotherapy. Therefore, radiotherapy is the fundamental treatment modality for NPC while cisplatin-based concurrent chemoradiotherapy is the standard treatment for locoregionally advanced NPC \[[@CR4]\]. Owing to great improvements in both diagnosis and radiation techniques, the prognosis of patients with non-metastatic NPC is quite satisfactory nowadays and the overall survival exceeds 80% \[[@CR5]\].

It has been estimated that 15% of NPC patients develop distant metastasis at the time of the first diagnosis, which is defined as de novo metastatic NPC \[[@CR6]\]. The prognosis of de novo metastatic NPC patients is poor even when treated with the first-line palliative chemotherapy regimen \[[@CR7]\]. However, the survival period varies greatly among these patients with different illness condition \[[@CR8]\]. Therefore, it is necessary to apply effective biomarkers for early survival prediction to guide individualized interventions.

In locoregionally advanced NPC, plasma Epstein-Barr virus (EBV) DNA levels have been proven to the most important biomarker, and it has been widely applied for condition monitoring and prognosis prediction \[[@CR9], [@CR10]\]. Furthermore, Li et al. have demonstrated the prognostic value of EBV DNA in metastatic NPC \[[@CR11]\]. Therefore, EBV DNA could facilitate risk stratification. The National Comprehensive Cancer Network (NCCN) guidelines recommend ^18^F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography and computed tomography (PET/CT) for the detection of distant metastases in stage III-IV NPC patients. The maximal standard uptake value (SUVmax), used for a (semi) quantitative analysis in PET/CT, was indicated to have remarkable prognostic value in head and neck cancers \[[@CR12]\]. In patients with non-metastatic NPC, previous studies have reported that the SUVmax represents a significant predictive factor of clinical outcomes \[[@CR13]--[@CR16]\]. However, to our knowledge, there is no related research on the predictive value of SUVmax in metastatic NPC.

Based on these facts, we conducted a retrospective study with a large sample size to investigate the utility of SUVmax in predicting survival outcomes in patients with de novo metastatic NPC in comparison with the prognostic value of EBV DNA, which would provide important information for personalized treatment.

Methods {#Sec2}
=======

Patient population {#Sec3}
------------------

From December 2006 to December 2016, 253 patients with de novo metastatic NPC diagnosed at the Sun Yat Sen University Cancer Center (SYSUCC) were included in this study. The inclusion criteria were as follows: (1) histologically confirmed NPC; (2) evidence of distant metastasis assessed by PET/CT; (3) use of cisplatin-based palliative chemotherapy (PCT); (4) an initial Karnofsky performance score of \> 70; (5) adequate renal and hepatic functions; and (6) no pregnancy, lactation, or second malignant disease. The flow chart is shown in Fig. [1](#Fig1){ref-type="fig"}. The analysis was approved by the clinical research ethics committee at SYSUCC. Fig. 1Flow chart showing patient inclusion

Diagnosis and treatment {#Sec4}
-----------------------

Prior to diagnosis, the patients underwent a series of assessments including a physical examination, nasopharyngoscopy and biopsy, enhanced magnetic resonance imaging (MRI) of the nasopharynx and neck, and PET/CT. Enhanced MRI/computed tomography (CT) of the metastatic sites or other tests were considered by clinical oncologists when necessary. Palliative chemotherapy was administered for all patients. The common chemotherapy regimens were GP (gemcitabine \[1000 mg/m^2^, d1,8\] and cisplatin \[20--30 mg/m^2^, d1--3\]), TPF (docetaxel \[60 mg/m^2^, d1\] combined with cisplatin \[60 mg/m^2^, d1\] and 5-fluorouracil (500--800 mg/m^2^, d1--5\]), PF (cisplatin \[20--25/m^2^, d1--3\] and 5-fluorouracil \[800--1000 mg/m^2^, d1--5\]), and TP (docetaxel \[75 mg/m^2^, d1\] plus cisplatin \[20--30 mg/m^2^, d1--3\]).

Chemotherapy was administered every 3 weeks intravenously. After PCT, 164 (64.8%) patients received locoregional radiotherapy (LRRT) using intensity-modulated radiation or two-dimensional conventional radiotherapy technique. The total dosage for radiation therapy was 68--70 Gy, five times a week from Monday to Friday, and 1.8--2.2 Gy each time.

EBV DNA measurement and PET/CT imaging test {#Sec5}
-------------------------------------------

Before treatment, patients' plasma EBV DNA was routinely measured by quantitative polymerase chain reaction as previously described \[[@CR17]\]. PET/CT was performed based on procedural guidelines \[[@CR18]\]. Forty-five to 60 min after the injection of FDG, PET/CT was performed from the head to the proximal thigh. Finally, with the use of CT data, the PET images were re-established \[[@CR6]\]. SUVmax was defined as the highest activity concentration per injected dose per body weight with correction of radioactive decay. SUVmax-T, SUVmax-N, and SUVmax-M referred to the SUVmax at the primary tumor, cervical lymph nodes, and metastatic lesions respectively.

Follow-up and outcome {#Sec6}
---------------------

After treatment, evaluations were conducted every 3 months for the first 3 years and then every 6 months thereafter until the patient died. Routine evaluations during follow-up included a physical examination; nasopharyngoscopy; enhanced MRI/CT of the nasopharynx, neck, and metastatic sites; chest X-ray/enhanced CT; and abdominal ultrasound/ enhanced CT. PET/CT or other tests were considered by clinical oncologists if necessary. The primary outcome of our study was overall survival (OS), and the definition of OS was the time from the date of diagnosis to the date of death from any cause.

Statistical analysis {#Sec7}
--------------------

The Spearman correlation test was used to evaluate the correlation between SUVmax and EBV DNA levels, which were regarded as continuous variables. The values of SUVmax and EBV DNA between survivors and non-survivors were compared using the Mann--Whitney U-test. The cut-off points for continuous variables were chosen by receiver operating characteristic (ROC) curve analysis following the Metz method \[[@CR19]\]. Patients' baseline characteristics were evaluated using the Chi-square test. Survival probabilities between patients in different groups were evaluated using the Kaplan--Meier method with log-rank test. Cox proportional hazards regression model was applied in the step-wise multivariate analysis. All statistical analyses were performed using Statistical Package for Social Sciences 23.0 (IBM Corporation, Armonk, NY, USA). All statistical tests were two-tailed, and *p* \< 0.05 was considered statistical significance.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

From December 2006 to December 2016, 253 de novo metastatic NPC patients were involved in the study. The median patient age was 47 years, and the male-to-female ratio was 5.8:1. In the cohort, 180 patients (71.1%) had one metastatic site, while 73 patients (28.9%) developed lesions at multiple metastatic sites on diagnosis. Other patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. The median follow-up period was 27.2 months \[interquartile range (IQR) 15.9--39.9 months\]. One hundred and thirty patients were dead at the last follow-up. The 3- and 5-year OS rates were 54.8 and 33.1%, respectively. Table 1Clinical characteristicsCharacteristicn(%)Total253Gender Male216(85.4%) Female37(14.6%)Age (years)  ≤ 47133(52.6%)  \> 47122(47.4%)T stage \# T112(4.7%) T222(8.7%) T3133(52.6%) T486(34.0%)N stage \# N04(1.6%) N128(11.1%) N294(37.2%) N3127(50.2%)Metastatic sites Bone116(45.8%) Lung28(11.1%) Liver14(5.5%) Distant nodes22(8.7%) Multiple sites73(28.9%)LRRT use No89(35.2%) Yes164(64.8%)*Abbreviations*: *LRRT* locoregional radiotherapyAccording to the 8th edition of the UICC/AJCC staging system

Distribution of SUVmax and EBV DNA level in survivors and non-survivors {#Sec10}
-----------------------------------------------------------------------

As shown in Fig. [2](#Fig2){ref-type="fig"}, patients who died during the follow-up period had significantly higher SUVmax-N (*P* = 0.026) and SUVmax-M (*P* = 0.006) values than patients alive at the last follow-up. However, there was no obvious difference in SUVmax-T between survivors and non-survivors (*P* = 0.615). Because the copy number of EBV DNA is obviously asymmetric, we obtained the logarithm of EBV DNA with the base 10 to make the distribution of values more uniform on coordinate axes. Obviously, the median EBV DNA level was higher in patients who were dead compared to patients who were survival (*P* = 0.001). Fig. 2The distribution of different variables in the survivor and non- survivor groups. **a** SUVmax-T; **b** SUVmax-N; **c** SUVmax-M; and **d** EBV DNA level

Correlation analysis between EBV DNA and SUVmax {#Sec11}
-----------------------------------------------

A Spearman correlation analysis was performed between SUVmax and EBV DNA levels (log~10~). The SUVmax and EBV DNA levels were regarded as continuous variables. Interestingly, SUVmax-N (R square = 0.090, *P* \< 0.001) and SUVmax-M (R square = 0.040, *P* = 0.001) were positively correlated with EBV DNA levels, while no significant correlation was found between SUVmax-T and EBV DNA levels (R square = 0.009, *P* = 0.130) (Fig. [3](#Fig3){ref-type="fig"}). It should be noted that although the results were significant, the correlations between SUVmax-N, SUVmax-M and EBV DNA levels were still weak. Fig. 3The correlations between SUVmax values and the EBV DNA level. **a** SUVmax-T; **b** SUVmax-N; and **c** SUVmax-M

Cut-off value of EBV DNA and SUVmax {#Sec12}
-----------------------------------

The ROC curve was applied to evaluate the ability of SUVmax and plasma EBV DNA to predict death and to choose the optimal cut-off value that showed the best trade-off between sensitivity and specificity in further analyses. According to the ROC analysis, the cut-off EBV DNA value was 13,800 copies/ml (sensitivity = 0.677, specificity = 0.528, area under curve \[AUC\] = 0.644) for OS (Fig. [4](#Fig4){ref-type="fig"}). The cut-off values of SUVmax-T, SUVmax-N, and SUVmax-M were 17.0, 12.7 and 6.9 respectively. The patient characteristics in different SUVmax and EBV DNA levels are shown in Table [2](#Tab2){ref-type="table"} and the follow-up durations of different subgroups are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Fig. 4Receiver operating characteristic (ROC) curve analysis used to determine the cut-off SUVmax values and EBV DNA level Table 2Clinical characteristics grouped by different SUV and EBV DNA levelSUVmax-T n(%)SUVmax-N n(%)SUVmax-M n(%)EBV DNA n(%)Characteristic*P* value*P* value*P* value*P* valueTotal175781041497717695158Gender Male148(84.6%)68(87.2%)0.70188(84.6%)128(85.9%)0.85767(87.0%)149(84.7%)0.70278(82.1%)138(87.3%)0.274 Female27(18.2%)10(12.8%)16(15.4%)21(14.1%)10(13.0%)27(15.3%)17(17.9%)20(12.7%)Age (years)  ≤ 4788(50.3%)45(57.7%)0.34049(47.1%)84(56.4%)0.16142(54.5%)91(51.7%)0.68450(52.6%)83(52.5%)\> 0.999  \> 4787(49.7%)33(42.3%)55(52.9%)65(43.6%)35(45.5%)85(48.3%)45(47.4%)75(47.5%)T stage \# T110(5.7%)2(2.6%)0.0897(6.7%)5(3.4%)0.1874(5.2%)8(4.5%)0.9845(5.3%)7(4.4%)**0.008** T219(10.9%)3(3.8%)7(6.7%)15(10.1%)7(9.1%)15(8.5%)15(15.8%)7(4.4%) T393(53.1%)40(51.3%)49(47.1%)84(56.4%)39(50.6%)94(53.4%)50(52.6%)83(52.5%) T453(30.3%)33(42.3%)41(39.4%)45(30.2%)27(35.1%)59(33.5%)25(26.3%)61(38.6%)N stage \# N04(2.3%)0(0.0%)0.525\*4(3.8%)0(0.0%)**\< 0.001\***2(2.6%)2(1.1%)0.332\*4(4.2%)0(0.0%)**0.002\*** N121(12.0%)7(9.0%)18(17.3%)10(6.7%)8(10.4%)20(11.4%)13(13.7%)15(9.5%) N266(37.7%)28(35.9%)42(40.4%)52(34.9%)34(44.2%)60(34.1%)42(44.2%)52(32.9%) N384(48.0%)43(55.1%)40(38.5%)87(58.4%)33(42.9%)94(53.4%)36(37.9%)91(57.6%)Metastatic site sites Bone87(49.7%)29(37.2%)0.05658(55.8%)58(38.9%)**0.005**31(40.3%)85(48.3%)**\< 0.001**47(49.5%)69(43.7%)**0.001** Lung20(11.4%)8(10.3%)13(12.5%)15(10.1%)13(16.9%)15(8.5%)17(17.9%)11(7.0%) Liver8(4.6%)6(7.7%)5(4.8%)9(6.0%)5(6.5%)9(5.1%)5(5.3%)9(5.7%) Distant nodes18(10.3%)4(5.1%)11(10.6%)11(7.4%)15(19.5%)7(4.0%)11(11.6%)11(7.0%) Multiple sites42(24.0%)31(39.7%)17(16.3%)56(37.6%)13(16.9%)60(34.1%)15(15.8%)58(36.7%)LRRT use No60(34.3%)29(37.7%)0.66834(33.3%)55(36.9%)0.59220(26.0%)69(39.4%)**0.045**28(29.5%)61(38.9%)0.137 Yes115(65.7%)48(62.3%)69(67.0%)94(63.1%)57(74.0%)106(60.6%)67(70.5%)96(61.1%)*Abbreviations*: *LRRT* locoregional radiotherapyAccording to the 8th edition of the UICC/AJCC staging systemThe *P* value was calculated with the Pearson χ2 test or Fisher's exact test (\*)Bold data referred to statistical significance (*P* \< 0.05)

Association between elevated SUVmax, EBV DNA levels and OS {#Sec13}
----------------------------------------------------------

We divided the patients into two different groups based on the cut-off SUVmax and EBV DNA values. In univariate analysis, patients with SUVmax-*N* \> 12.7 showed a lower 3-year OS than patients with SUVmax-*N* ≤ 12.7 (65.1% vs. 46.5%, *P* = 0.005). Similarly, in comparison with patients with SUVmax-M \> 6.9, patients with SUVmax-M ≤ 6.9 achieved a better survival condition (65.4% vs. 49.2%, *P* = 0.005). However, the 3-year OS was comparable among patients with different SUVmax-T levels (57.3% vs. 47.7%, *P* = 0.484). In terms of EBV DNA, the patients EBV DNA ≥ 13,800 copies/mL showed a worse survival condition than patients with lower EBV DNA level. The 3-year OS was 70.4 and 44.7%, respectively (*P* = 0.001). The Kaplan--Meier curve for OS is shown in Fig. [5](#Fig5){ref-type="fig"}. Fig. 5Kaplan--Meier survival curves comparing overall survival grouped by the cut-off SUVmax-T (**a**), SUVmax-N (**b**), and SUVmax-M (**c**) values and the EBV DNA level (**d**). *P* values were calculated using the log-rank test

Multivariate analyses of prognostic factors {#Sec14}
-------------------------------------------

We further used three multivariate analysis models in our study (Table [3](#Tab3){ref-type="table"}). In model 1, SUVmax-T, SUVmax-N, and SUVmax-M were involved in the analysis and only SUVmax-M was associated with OS (hazard ratio \[HR\]: 1.72, 95% confidence interval \[CI\]: 1.13--2.78, *P* = 0.012). In model 2, which was adjusted for EBV DNA level, both SUVmax-M and EBV DNA remained independent factors for OS. Finally, other risk factors (T stage, N stage, age, gender, metastatic site, and LRRT use) were considered. In model 3, EBV DNA level still remained an independent prognostic factor for OS (HR: 1.55, 95% CI: 1.03--1.23, *P* = 0.036) while SUVmax-M did not. Patients with multiple metastatic sites exhibited worse OS than patients with bone-only metastasis (HR, 1.87; 95% CI, 1.25--2.80, *P* = 0.002). Besides, LRRT use was a protective factor (HR, 0.51; 95% CI, 0.35--0.78; *P* \< 0.001). Table 3Multivariate analysesModel 1Model 2Model 3CharacteristicHR (95%CI)*P* valueHR (95%CI)*P* valueHR (95%CI)*P* valueSUVmax-TNSNSNSSUVmax-N1.40(0.95--2.06)0.087NSNSSUVmax-M1.72(1.13--2.78)0.0121.72(1.10--2.67)0.017NSEBV-DNA1.62(1.08--2.43)0.0201.55(1.03--2.32)0.036Metastatic site Lung vs. Bone0.74(0.38--1.41)0.357 Liver vs. Bone1.10(0.52--2.32)0.805 Distant nodes vs. Bone0.50(0.18--1.39)0.184 Multiple vs. Bone1.87(1.25--2.80)0.002LRRT0.51(0.35--0.78)\< 0.001*Abbreviations*: *NS* non-significant, *HR* hazard ratio, *CI* confidence interval, *LRRT* locoregional radiotherapyBackward step-wise multivariate analyses using Cox proportional hazard model was applied to select variables. Only variables that were significant associated with overall survival are presentedHRs were calculated for SUVmax-T (\> 17.0 vs. ≤17.0); SUVmax-N (\> 12.7 vs. ≤12.7); SUVmax-M (\> 6.9 vs. ≤6.9); EBV DNA (\> 13,800 copies/ml vs. ≤13,800 copies/ml); LRRT (Yes vs. No)

Discussion {#Sec15}
==========

As far as we know, this is the first retrospective cohort study to explore the prognostic value of EBV DNA levels and SUVmax values in de novo metastatic NPC patients. Here, we found that SUVmax-N and SUVmax-M of ^18^F-FDG PET/CT had positive correlations with EBV DNA levels while SUVmax-T did not. Furthermore, SUVmax-N and SUVmax-M were related to the patients' prognosis. EBV DNA level was superior to SUVmax in terms of its survival prediction value and remained an independent factor in multivariate analyses combining other risk factors.

EBV DNA level was an important biomarker for NPC as previous studies investigated \[[@CR9], [@CR10], [@CR20]\]. Lin et al. demonstrated that higher EBV DNA levels (\> 1500 copies/mL) prior to treatment or detectable levels after treatment were both related to lower OS for non-metastatic NPC patients \[[@CR9]\]. The prognostic value is similar among metastatic and recurrent patients \[[@CR11]\]. In our previous study, we established a prognostic nomogram combining EBV DNA level and other prognostic factors. The new model showed better discrimination than the traditional TNM stage \[[@CR21]\]. Additionally, we demonstrated that the pretreatment plasma EBV DNA level was of great value in predicting distant metastasis for NPC patients, making the use of PET-CT more reasonable \[[@CR6]\]. 18F-FDG uptake, which was measured by SUVmax, was related to the glucose metabolic rate of tumor cells. Previous studies have reported that non-metastatic NPC patients with lower SUVmax values achieved better survival rates \[[@CR13], [@CR16], [@CR22]\]. Zhang et al. were the first group to develop an integrated prognostic model based on recursive partitioning analysis for DMFS, which incorporated SUVmax-N and N-classification \[[@CR23]\]. In addition, Sher et al. demonstrated that NPC patients with higher SUVmax values had a worse 5-year OS, and the SUV75% on FDG PET could be used to identify patients benefiting from adjuvant chemotherapy \[[@CR24]\].

In locoregionally advanced NPC, we have the verified the predictive value of SUVmax and EBV DNA level in previous study \[[@CR25]\]. However, there was no relevant research on de novo metastatic NPC. In this study, we found that higher levels of SUVmax-N and SUVmax-M were significantly associated with a lower 3-year OS, but the SUVmax-T result was not. On the other hand, the EBV DNA level exhibited a superior predictive ability. Patients with a higher EBV DNA level suffered lower 3-year OS compared with other patients (70.4% vs. 44.7%, *P* \< 0.001). Multifactorial Cox regression analysis suggested that for the OS, the independent prognostic factors included the EBV DNA level, metastatic sites, and LRRT use, but the SUVmax at any site was not involved. Additionally, we found that there were strong correlations between SUVmax-N, SUVmax-M values and the metastatic sites according to the Chi-square test (Table [2](#Tab2){ref-type="table"}). According to the theory of multicollinearity, if there was a significant correlation between two prognostic factors in the Cox proportional hazards regression model, their predictive values would be influenced by each other. This may partially explain why these two factors did not remain independent prognostic factors in multivariate analysis. Our results showed that the EBV DNA level, which is the best biomarker so far, was more sensitive than SUVmax value for prediction of death in de novo metastatic NPC.

According to this study, a high level of SUVmax-N, SUVmax-M, and EBV DNA indicated worse prognosis in metastatic NPC patients at diagnosis. For these patients, closer follow-up examinations and early intervention were necessary. Cisplatin-based PCT has been established as the standard treatment regimen for metastatic NPC patients \[[@CR7], [@CR26]--[@CR28]\]. Recently, several studies verified that LRRT could further improve patients' survival when combined with PCT in metastatic NPC patients \[[@CR8], [@CR29]\]. Our results were consistent with these previous studies, which demonstrated that LRRT was a significant protective factor in multivariate analysis. Nevertheless, the current regular treatment therapy may not be adequate to improve the OS for high-risk patients. A new treatment method urgently needs to be identified. On the basis of this fact, our group initiated a worldwide, multicenter, phase III clinical study of cisplatin and gemcitabine with or without PD-1 antibody (toripalimab) in patients with recurrent or metastatic NPC (NCT 03581786). We are looking forward to the findings.

Several limitations existed in the current study. First, this was a retrospective study and the selection bias could not be eliminated. Second, all patients in current study were from one treatment center, and the pathology type of most patients was WHO type III. Third, the global standards for EBV DNA measurement are different, which need for further standardization. A prospective study from multiple institutions is needed to confirm our results.

Conclusion {#Sec16}
==========

De novo metastatic NPC patients with high levels of SUVmax-N and SUVmax-M at diagnosis had a poor prognosis. Pre-EBV DNA level showed a stronger predictive ability than SUVmax and was the independent prognostic factor.

Additional file
===============

 {#Sec17}

Additional file 1:**Table S1.** Follow-up durations of different subgroups (DOCX 51 kb)
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